Risks of Depakote (Valproic Acid) as Mood Stabilizer in a 74-Year-Old Male Nursing Home Patient
Valproic acid carries substantial risks in elderly nursing home patients and is likely ineffective for behavioral symptoms, making it a poor choice for mood stabilization in this population.
Critical Safety Concerns
Hepatotoxicity
The FDA label warns of serious liver damage that can cause death, with risk highest in the first 6 months of treatment 1. Watch for:
- Weakness, fatigue, malaise
- Nausea, vomiting, anorexia
- Right upper quadrant abdominal pain
- Dark urine, jaundice
- Loss of seizure control (if applicable)
Mandatory liver function monitoring is required before and during treatment 1.
Pancreatitis
Life-threatening pancreatitis can occur and requires immediate evaluation if the patient develops 1:
- Severe abdominal pain (may radiate to back)
- Persistent nausea/vomiting
- Loss of appetite
Neurological Complications
Hyperammonemic encephalopathy is a serious concern in elderly patients, even without elevated ammonia levels 2. Clinical presentation includes:
- Altered mental status, somnolence, disorientation
- Staring, mutism, bradyphrenia
- Extrapyramidal symptoms, akathisia
- Hyperreflexia
This condition is reversible upon discontinuation but may be mistaken for dementia progression 2.
Hematologic Risks
Thrombocytopenia can develop, particularly in the first 6 months, requiring close platelet monitoring 3. This increases bleeding risk in elderly patients already at higher fall risk.
Cognitive and Functional Decline
Moderate-quality evidence shows valproate may worsen functional ability in elderly patients (Physical Self-Maintenance Scale scores worsened by 1.19 points) 4. The clinical significance is uncertain but concerning in nursing home residents with already limited function.
Increased dementia risk: A 2022 study found valproate-only users had a 59% higher risk of dementia compared to non-users, with risk increasing after 59 days or 23 cumulative defined daily doses 5. Lithium showed no such association, making it potentially safer for elderly bipolar patients 5.
Efficacy Concerns
Lack of Evidence for Agitation/Behavioral Symptoms
Moderate-quality evidence demonstrates valproate is probably ineffective for agitation in dementia 4. A Cochrane review of 5 studies (430 participants) found:
- No benefit on BPRS total scores (MD 0.23,95% CI -2.14 to 2.59)
- No benefit on BPRS agitation factor (MD -0.67,95% CI -1.49 to 0.15)
- No benefit on Cohen-Mansfield Agitation Index
Off-Label Use Driving Prescribing Trends
A 2025 national survey revealed that 97% of nursing home clinicians reported off-label valproate use for psychiatric symptoms drives observed increases in prescribing 6. Clinicians acknowledged this represents a strategy to circumvent regulatory scrutiny of antipsychotics and benzodiazepines, not evidence-based practice 6.
Adverse Event Profile
Low-quality evidence indicates valproate-treated patients may experience twice the rate of adverse effects (OR 2.02,95% CI 1.30 to 3.14) 4, including:
- Sedation (particularly problematic for fall risk)
- Gastrointestinal symptoms (nausea, vomiting, diarrhea)
- Urinary tract infections
Serious adverse events may be nearly 5 times more likely (OR 4.77,95% CI 1.00 to 22.74), though evidence quality is very low 4.
CNS Depression and Falls
Valproate causes CNS depression, especially when combined with other sedating medications common in nursing homes (e.g., benzodiazepines, opioids) 1. This substantially increases fall risk in an already vulnerable population.
Regulatory and Clinical Context
While the 2019 AGS Beers Criteria does not specifically list valproate as a potentially inappropriate medication 7, the 2025 British Journal of Pharmacology guidelines emphasize that aged care-specific evidence is lacking for many medications, and clinical decision support tools like Beers Criteria "are not specific to the aged care home or end-of-life care settings" 8.
The FDA mandated nursing home reporting of anti-seizure medications (including valproate) beginning October 2024, recognizing the need for oversight similar to other psychotropics 6.
Common Pitfalls to Avoid
- Assuming valproate is "safer" than antipsychotics: The evidence suggests otherwise in elderly nursing home patients
- Continuing therapy without clear benefit: If prescribed for behavioral symptoms, lack of efficacy should prompt discontinuation
- Inadequate monitoring: Liver function, platelets, and ammonia levels require regular assessment
- Abrupt discontinuation: Must taper gradually to avoid withdrawal seizures if used for epilepsy 1
- Polypharmacy interactions: CNS depression risk multiplies with concurrent sedating medications
Clinical Recommendation
For this 74-year-old male nursing home patient, valproate poses significant risks with questionable benefit for mood stabilization or behavioral symptoms. If bipolar disorder requires treatment, lithium may be safer regarding dementia risk 5. For agitation or behavioral symptoms, non-pharmacological interventions should be prioritized, with careful consideration of alternative medications only when absolutely necessary 4.